Cell Culture Market, By Product (Consumables, Instruments), By Application (Biopharmaceutical Production, Tissue Culture & Engineering, Toxicity Testing, Drug Development, Cell & Gene Therapy, and Others), By End User (Biopharmaceutical Companies, Hospitals & Diagnostic Laboratories, CMO & CRO, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024

Code : CMI116

Pages :160

Formats :

Excel and PDF

Industry : Biotechnology

Key Developments

On February 7, 2024, 10x Genomics, Inc., a frontrunner in single cell and spatial biology solutions, unveiled GEM-X, the newest iteration of its acclaimed single cell technology. Representing the primary advancement to the chromium framework since the introduction of Next GEM technology in 2019, GEM-X is constructed upon an innovative microfluidic chip design, incorporating cutting-edge technological advancements and refined reagents to ensure unmatched performance and robust reliability.
On January 24, 2024, Merck & Co., Inc., a prominent science and technology enterprise, announced that its Life Science division has entered into a non-binding Memorandum of Understanding (MoU) with Mycenax Biotech, a specialized biologics Contract Development and Manufacturing Organization (CDMO), with the aim of investigating potential collaboration opportunities for introducing pioneering and scalable bioprocessing solutions to Taiwan and various global markets
In September 2023, PhenomeX Inc., a company specializing in functional cell biology, revealed that GSK plc, a biopharmaceutical firm, will showcase findings on the SpotLight Human Lambda reagent for the Beacon platform at the 16th annual Conference on Protein Expression in Animal Cells, scheduled to take place in Sitges, Spain, from September 24-28, 2023
In January 2023, Curate Biosciences, a player in the life sciences sector, announced the official release of its groundbreaking Curate Cell Processing System. As the pioneer in its category, the Curate System yields top-tier starting materials crucial for CAR-T cancer therapy and other cell therapies. Leveraging an exceptionally precise microfluidic approach, it achieves approximately 90% recovery of white blood cells while successfully removing over 90% of red cells and 99% of platelets from leukapheresis blood products obtained from patients. This process results in cells that enhance transduction efficiency for therapeutic manufacturing.